GRAIL (GRAL) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $28.7 million, a 38% increase year-over-year, driven by strong Galleri test demand and commercial execution, with over 250,000 tests prescribed since launch.

• The company completed a spin-off from Illumina in June 2024, becoming an independent public entity listed on NASDAQ.

• A restructuring plan in Q3 2024 prioritized the core MCED business, reduced costs, and extended the cash runway into 2028.

• The company is preparing to launch a more automated version of Galleri to support scalability and cost reduction.

Financial highlights

• Q3 2024 revenue was $28.7 million, up 38% year-over-year, with Galleri revenue growing 52% to $25.4 million and development services revenue at $3.3 million.

• Net loss for Q3 2024 was $125.7 million, an 86% improvement from Q2 2023, with adjusted EBITDA at $(108.2) million, a 14% improvement year-over-year.

• Adjusted gross profit for Q3 was $11.8 million, up 68% year-over-year, and gross loss improved to $(22.2) million.

• Cash and cash equivalents as of September 30, 2024, were $853.6 million.

• Net loss per share was $(3.94), compared to $(28.71) in the prior year quarter.

Outlook and guidance

• Galleri sales growth for 2024 is expected to be between 40% and 50% over 2023.

• Full-year 2025 cash burn is guided to approximately $325 million, with reductions expected in subsequent years.

• Cash runway is projected to extend into 2028 following spending reductions and restructuring.

• FDA PMA submission for Galleri is targeted for the first half of 2026, with potential approval in the first half of 2027.

• Anticipated results from major registrational studies in 2025 and 2026.